| General information |
| Database: | DB00913 |
| Objective: | they studied the efficacy of cetuximab therapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oral inhibitor of the tyrosine kinase domain of the epidermal growth factor receptor |
| Authors: | Meyerhardt JA, et al |
| Title: | Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitorbased chemotherapy in metastatic colorectal cancer. |
| Journal: | Clin Colorectal Cancer |
| Year: | 2006 |
| PMID: | 16796793 |
| Trial Design |
| Clinical Trial Id: | NA |
| Agent: | cetuximab
|
| Target: | Epidermal growth factor receptor
|
| Cancer Type: | colorectal cancer |
| Cancer Subtype: | advanced colorectal cancer |
| Therapy Type: | mono |
| Therapeutic Combination Type: | NA |
| Therapeutic Combination Content: | NA |
| Study Type: | posthoc analysis |
| Key Patients Feature: | patients with mCRC who participated in 1 of 3 clinical trials that examined a combination of gefitinib or erlotinib with standard cytotoxic chemotherapy. |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | Medical and pharmacy records were used to identify patients who were subsequently treated with cetuximabbased therapy. Computed tomography scans during cetuximabbased therapy were revietheyd, and the clinical activity of cetuximab was assessed by response rate using Response Evaluation Criteria in Solid Tumors and progression free survival |
| Primary End Point: | efficacy |
| Secondary End Point: | NA |
| Patients Number: | 24 |
| Trial Results |
| DLT_MTD: | NA |
| Objective Response Rate: | 0% |
| Disease Control Rate: | 72% |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | 5.1 months for all patients |
| Median OS A vs. C: | NA |
| Adverse Event(agent arm): | NA |
| Conclusions: | Cetuximab appears to have clinical benefit in patients with mCRC previously treated with a chemotherapy regimen that included an oral tyrosine kinase inhibitor of epidermal growth factor receptor. Whether these results apply to other cancer types is unknown but worthy of further study. |